Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma

被引：0
|
作者：
Barr, Hallie
Dempsey, Jessica
Waller, Allyson
Huang, Ying
Williams, Nita
Sharma, Nidhi
Benson, Don M., Jr.
Rosko, Ashley E.
Efebera, Yvonne A.
Hofmeister, Craig C.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1889
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group
    Federico Vozella
    A. Siniscalchi
    M. Rizzo
    T. Za
    G. Antolino
    U. Coppetelli
    A. Piciocchi
    A. Andriani
    O. Annibali
    L. De Rosa
    G. Cimino
    G. La Verde
    V. De Stefano
    M. Cantonetti
    T. Caravita di Toritto
    M. T. Petrucci
    Annals of Hematology, 2021, 100 : 1059 - 1063
  • [32] Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis
    Rosko, Nathaniel
    Mo, Hanjie
    Rudoni, Joslyn
    Siebenaller, Caitlin
    Lee, Sarah S.
    Chakraborty, Rajshekar
    Faiman, Beth M.
    Khouri, Jack
    Garcia, Alex V. Mejia
    Samaras, Christy J.
    Anwer, Faiz
    Valent, Jason
    BLOOD, 2019, 134
  • [33] SAFETY AND TOLERABILITY OF RAPID INTRAVENOUS INFUSION OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A TERTIARY CENTER
    Gutierrez, Lopez de Ocariz X.
    Cuellar, Perez-Avila C.
    Vera, Guerrero E.
    De Nicolas, Sol R.
    Buendia, Urena B.
    Lopez, Munoz N.
    Hidalgo, Soto M.
    Zamanillo, Herreros, I
    Poza, Santaella M.
    Iniguez, Garcia R.
    Sanchez, Pina J. M.
    Alonso, Fernandez R.
    Lahuerta, Palacios J. J.
    Martinez, Lopez J.
    HAEMATOLOGICA, 2020, 105 : 146 - 146
  • [34] Quality improvement project for prevention of infusion related reactions of daratumumab therapy in multiple myeloma patients
    Jindal, Vishal
    Shepro, David Scott
    Pranckevicius, Leigh
    Siddiqui, Ahmad Daniyal
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis
    Hughes, David M.
    Henshaw, Lynnette
    Blevins, Frances
    Edwards, Camille
    Lerner, Adam
    Sloan, John Mark
    Sanchorawala, Vaishali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : 566 - 568
  • [36] Daratumumab in dialysis-dependent multiple myeloma
    Jeyaraman, Preethi
    Bhasin, Alka
    Dayal, Nitin
    Pathak, Sangeeta
    Naithani, Rahul
    BLOOD RESEARCH, 2020, 55 (01) : 65 - 67
  • [37] Daratumumab in untreated newly diagnosed multiple myeloma
    Abdallah, Nadine
    Kumar, Shaji K.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [38] Daratumumab subcutaneous formulation for the treatment of multiple myeloma
    Paul, Barry
    Hamadeh, Issam
    Atrash, Shebli
    Bhutani, Manisha
    Voorhees, Peter
    Usmani, Saad Z.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (11) : 1253 - 1259
  • [39] REAL WORLD EVIDENCE OF DARATUMUMAB IN MULTIPLE MYELOMA
    Barros, C.
    Raposo, J. P.
    Caetano, F. R.
    VALUE IN HEALTH, 2019, 22 : S444 - S444
  • [40] Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice
    Hamadeh, Issam S.
    Arnall, Justin
    Kachur, Ekaterina
    Martin, Allison
    Jagosky, Megan Helena
    Friend, Reed
    Atrash, Shebli
    Bhutani, Manisha
    Voorhees, Peter M.
    Usmani, Saad Z.
    BLOOD, 2018, 132
12345